Member News

'Patent to Patient' looks at regulatory delays in drug innovation

The Institute for Cancer Research, London, has released a report looking at cancer drug delivery in the NHS and the rate of drug development across different types of cancer. ‘Patent to Patient’  analysed the regulatory regime and found that NHS patients are waiting longer for new cancer drugs because of delays in taking them through clinical trials and getting them approved for use.